FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284411> ?p ?o ?g. }

• W4379284411 endingPage "2059" @default.
• W4379284411 startingPage "2059" @default.
• W4379284411 abstract "2059 Background: Tumor Treating Fields (TTFields) are electric fields that exert forces on cancer cells, disrupting processes critical for cancer cell viability and tumor progression. TTFields therapy became an FDA-approved treatment option for patients with newly diagnosed glioblastoma (GBM) in 2015 on the basis of the randomized controlled EF-14 study (NCT00916409). Subsequent approvals worldwide and increased adoption of TTFields has led to the question of whether or not a consistent survival benefit has been observed in the real-world setting, and whether device usage has played a role. Methods: A literature search was conducted using PubMed, Embase, and the Cochrane Library to identify clinical studies evaluating overall survival in adult patients with GBM treated with TTFields therapy. Comparative studies and single-cohort studies reporting on survival outcomes were included in the analysis. Inter-study heterogeneity was assessed using the Cochran Q test and quantified using the Higgins I 2 statistic. Survival curves were pooled using a distribution-free random-effects method. Results: Our review identified 8 studies evaluating the clinical efficacy of TTFields therapy in newly diagnosed GBM, with patients spanning diverse geographic regions. Of these 8, 6 studies (reporting on a total of 1378 patients) compared the addition of TTFields therapy to standard of care (SOC) vs SOC alone, and were included in a pooled analysis for overall survival. Meta-analysis of comparative studies indicated a significant improvement in overall survival for patients treated with TTFields therapy vs those not receiving treatment (hazard ratio [HR]: 0.62; 95% CI, 0.52–0.73; P < 0.001). Inter-study heterogeneity was examined, and a sensitivity analysis indicated the pooled effect was robust and not dependent on any individual study. Among post-approval studies, the pooled median overall survival was 22.2 months (95% CI, 17.3–42.6) for TTFields-treated patients and 17.3 months (95% CI, 13.6–22.0) for the non-TTFields group. Rates of gross total resection were generally higher in the real-world setting, irrespective of TTFields use. Furthermore, among studies reporting data on TTFields device usage, an average device usage rate of 75% or higher was found to consistently associate with prolonged survival when compared to an average usage rate below 75% (pooled HR: 0.63; 95% CI, 0.48–0.83; P = 0.001). Conclusions: Meta-analysis of comparative studies suggests a significant survival benefit with TTFields therapy added to standard radiochemotherapy for patients with newly diagnosed GBM, and that a 75% usage rate may be meaningful in the real-world setting." @default.
• W4379284411 created "2023-06-05" @default.
• W4379284411 creator A5002521351 @default.
• W4379284411 creator A5002646958 @default.
• W4379284411 creator A5046915343 @default.
• W4379284411 creator A5049593976 @default.
• W4379284411 creator A5070251132 @default.
• W4379284411 creator A5078489157 @default.
• W4379284411 creator A5091378683 @default.
• W4379284411 date "2023-06-01" @default.
• W4379284411 modified "2023-10-16" @default.
• W4379284411 title "Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review." @default.
• W4379284411 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.2059" @default.
• W4379284411 hasPublicationYear "2023" @default.
• W4379284411 type Work @default.
• W4379284411 citedByCount "0" @default.
• W4379284411 crossrefType "journal-article" @default.
• W4379284411 hasAuthorship W4379284411A5002521351 @default.
• W4379284411 hasAuthorship W4379284411A5002646958 @default.
• W4379284411 hasAuthorship W4379284411A5046915343 @default.
• W4379284411 hasAuthorship W4379284411A5049593976 @default.
• W4379284411 hasAuthorship W4379284411A5070251132 @default.
• W4379284411 hasAuthorship W4379284411A5078489157 @default.
• W4379284411 hasAuthorship W4379284411A5091378683 @default.
• W4379284411 hasConcept C10515644 @default.
• W4379284411 hasConcept C121608353 @default.
• W4379284411 hasConcept C126322002 @default.
• W4379284411 hasConcept C143998085 @default.
• W4379284411 hasConcept C201903717 @default.
• W4379284411 hasConcept C207103383 @default.
• W4379284411 hasConcept C2776194525 @default.
• W4379284411 hasConcept C2776478404 @default.
• W4379284411 hasConcept C44249647 @default.
• W4379284411 hasConcept C502942594 @default.
• W4379284411 hasConcept C535046627 @default.
• W4379284411 hasConcept C71924100 @default.
• W4379284411 hasConcept C95190672 @default.
• W4379284411 hasConceptScore W4379284411C10515644 @default.
• W4379284411 hasConceptScore W4379284411C121608353 @default.
• W4379284411 hasConceptScore W4379284411C126322002 @default.
• W4379284411 hasConceptScore W4379284411C143998085 @default.
• W4379284411 hasConceptScore W4379284411C201903717 @default.
• W4379284411 hasConceptScore W4379284411C207103383 @default.
• W4379284411 hasConceptScore W4379284411C2776194525 @default.
• W4379284411 hasConceptScore W4379284411C2776478404 @default.
• W4379284411 hasConceptScore W4379284411C44249647 @default.
• W4379284411 hasConceptScore W4379284411C502942594 @default.
• W4379284411 hasConceptScore W4379284411C535046627 @default.
• W4379284411 hasConceptScore W4379284411C71924100 @default.
• W4379284411 hasConceptScore W4379284411C95190672 @default.
• W4379284411 hasFunder F4320313690 @default.
• W4379284411 hasIssue "16_suppl" @default.
• W4379284411 hasLocation W43792844111 @default.
• W4379284411 hasOpenAccess W4379284411 @default.
• W4379284411 hasPrimaryLocation W43792844111 @default.
• W4379284411 hasRelatedWork W2039727033 @default.
• W4379284411 hasRelatedWork W2056185445 @default.
• W4379284411 hasRelatedWork W2581928246 @default.
• W4379284411 hasRelatedWork W2623600402 @default.
• W4379284411 hasRelatedWork W2734975679 @default.
• W4379284411 hasRelatedWork W2739667433 @default.
• W4379284411 hasRelatedWork W2799310318 @default.
• W4379284411 hasRelatedWork W3024842894 @default.
• W4379284411 hasRelatedWork W3157589766 @default.
• W4379284411 hasRelatedWork W3173197596 @default.
• W4379284411 hasVolume "41" @default.
• W4379284411 isParatext "false" @default.
• W4379284411 isRetracted "false" @default.
• W4379284411 workType "article" @default.